SCHEMBL16632561

SCHEMBL16632561

COc1cc(F)c(F)cc1Oc1cccn2cc(C#N)cc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 4/20 0.41
GRM5 P41594 4/20 0.37
SLC22A12 Q96S37 1/20 0.36
ALDH1A1 P00352 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KDM4E B2RXH2 3/20 0.33
HPGDS O60760 1/20 0.33
GLA P06280 1/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
PDE2A O00408 1/20 0.32
PDE10A Q9Y233 1/20 0.32
LMNA P02545 1/20 0.32
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16632347 0.89 GRM5 (0.41) ARGRM5SLC22A12ALDH1A1SMN1; SMN2
SCHEMBL16632728 0.89 AR (0.46) ARGRM5SLC22A12ALDH1A1SMN1; SMN2
SCHEMBL16632488 0.87 AR (0.48) ARGRM5ALDH1A1SMN1; SMN2NPC1
SCHEMBL16632725 0.85 GRM5 (0.34) ARGRM5
SCHEMBL16632744 0.83 SLC6A4 (0.50) ARSLC22A12SMN1; SMN2KDM4ELMNA
SCHEMBL16632583 0.82 GRM5 (0.38) ARGRM5SLC22A12SLC6A4
SCHEMBL16632571 0.78 GRM5 (0.37) ARGRM5ALDH1A1KDM4E
SCHEMBL16632602 0.78 GRM5 (0.37) ARGRM5ALDH1A1KDM4E
SCHEMBL16632447 0.76 AR (0.39) ARGRM5SLC22A12GAALMNA
SCHEMBL16632341 0.76 AR (0.45) ARGRM5SLC22A12ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9382245-B2 Compounds and methods for treating HIV infections YALE UNIVERSITY (US) 2016-07-05 US disclosed
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS POLM, POLRMT, DHFR AR 3070/4885GRM5 2115/4885SLC22A12 2889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.